Viral cultures for COVID-19 infectivity assessment – a systematic review

In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Jefferson T1; Spencer EA1; Brassey J2; Heneghan C1.

Affiliations
1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Oxford, OX2 6GG
2. Trip Database Ltd

Keywords: Covid-19; mode of transmission, viral culture; symptom onset to test date; polymerase chain reaction; SARS-CoV-2; infectivity.

Joint corresponding authors:
Jefferson (tom-jefferson@conted.ox.ac.uk)
Heneghan (Carl.heneghan@phc.ox.ac.uk)

Summary
Objective to review of the evidence from studies comparing SARS-CoV-2 culture, the best indicator of current infection and infectiousness with the results of reverse transcriptase polymerase chain reaction (RT-PCR).

Methods We searched LitCovid, medRxiv, Google Scholar and Google for Covid-19 for 'viral culture' or 'viral replication' and associated synonyms up to 18th August 2020. We carried out citation matching and included studies reporting attempts to culture or observe SARS-CoV-2 matching the with cutoffs for RT-PCR positivity. One reviewer extracted data for each study and a second review checked and edited the extraction and summarised the narratively by sample: fecal, respiratory, environment or mixed. Where necessary we wrote to corresponding authors of the included or background papers for additional information. We assessed quality using a modified QUADAS 2 risk of bias tool.

This review is part of an Open Evidence Review on Transmission Dynamics of COVID-19. Summaries of the included studies and the protocol (v1) are available at: https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/. Searches are updated every 2 weeks.

Results We included 17 studies reporting culturing or observing tissue invasion by SARS-CoV in sputum, naso or oropharyngeal, urine, stool and environmental samples from patients diagnosed with Covid-19. The data are suggestive of a relation between the time from collection of a specimen to test, cycle threshold (as a proxy for viral load) and symptom severity. The quality of the studies was moderate with lack of standardised reporting and lack of testing of PCR against viral culture or infectivity in animals limiting our current ability to quantify the relationship between the variables and ultimately the usefulness of PCR use for...
Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

assessing infectiousness of patients. Infectivity appears to decline after about a week of viral shedding around the cycle threshold value of 24.

Conclusion
Prospective routine testing of reference and culture specimens are necessary for each country involved in the pandemic to establish the usefulness and reliability of PCR for Covid-19 and its relation to patients’ factors such as date of onset of symptoms and copy threshold, in order to help predict infectivity.
Introduction

The ability to make decisions on the prevention and management of COVID-19 infections rests on our capacity to identify those who are infected and infectious. In the absence of predictive clinical signs or symptoms, the most widely used means of detection is molecular testing using Reverse Transcriptase quantitative Polymerase Chain Reaction (RT-qPCR)²³. The test amplifies genomic sequences identified in samples. As it is capable of generating observable signals from small samples, it is very sensitive. Amplification of genomic sequence is measured in cycle thresholds (Ct). There appears to be a correlation between Ct values from respiratory samples, symptom onset to test (STT) date and positive viral culture. The lower the Ct value (as a proxy for total viral load) and the shorter the STT, the higher the infectivity potential⁴.

Whether probing for sequences or whole genomes, in the diagnosis of Covid-19 a positive RT-qPCR cannot tell you whether the person is infectious or when the infection began, nor the provenance of the genetic material. Very early in the COVID-19 outbreak it was recognised that cycle threshold values are a proxy for quantitative measure of viral load, but correlation with clinical progress and transmissibility was not yet known.⁶ A positive result indicates that a person has come into contact with the genomic sequence or some other viral antigen at some time in the past. However, presence of viral genome on its own is not sufficient proof of infectivity and caution is needed when evaluating the infectivity of specimens simply based on the detection of viral nucleic acids.⁵ In addition, viral genomic material can be still be present weeks after infectious viral clearance.⁷ Like all tests, RT-qPCR requires validation against a gold standard. In this case isolation of a whole virion (as opposed to fragments) and proof that the isolate is capable of replicating its progeny in culture cells is the closest we are likely to get to a gold standard.⁸

Our Open Evidence Review of transmission modalities of SARS CoV-2 identified a low number of studies which have attempted viral culture. There are objective difficulties in doing such cultures such as the requirement for a level III laboratory, time and the quality of the specimens as well as financial availability of reagents and culture media to rule out the presence of other pathogens.

As viral culture represents the best indicator of infection and infectiousness, we set out to review the evidence on viral culture compared to PCR, and report the results of those studies attempting viral culture regardless of source (specimen type) of the sample tested.

Methods

We conducted an initial search using LitCovid, medRxiv, Google Scholar and Google for Covid-19 using the terms ‘viral culture’ or ‘viral replication’ and associated synonyms. Search last updated 18th August 2020. We reviewed the results for relevance and the searches were stopped when no new relevant articles were apparent. For articles that looked particularly relevant, citation matching was undertaken and relevant results were identified.

We included studies reporting attempts to culture SARS-CoV-2 and those which also estimated the infectiousness of the isolates or observed tissue invasion by SARS CoV-2. One reviewer extracted data for each study and a second review checked and edited the extraction. We tabulated the data and summarised data narratively by mode of sample: fecal, respiratory, environment or mixed.
Where necessary we wrote to corresponding authors of the included or background papers for additional information. We assessed quality using a modified QUADAS 2 risk of bias tool. We simplified the tool as the included studies were not designed as primary diagnostic accuracy studies.9

This review is part of an Open Evidence Review on Transmission Dynamics of COVID-19. Summaries of the included studies and the protocol (v1) are available at: https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/. Searches are updated every 2 weeks.

Results

We identified 118 articles of possible interest and after screening full texts included 17 (see PRISMA10 flow chart - Figure 1). We identified one unpublished study which was not included as no permission to do so was given by the authors. The salient characteristics of each included study are shown in Table 1.

All 14 studies were case series of moderate quality (Table 2. Quality of included studies). We could not identify a protocol for any of the studies. All the included studies had been either published or were available as preprints; all had been made public in 2020. We received four responses from authors regarding clarifying information (see Acknowledgments).

Studies using fecal samples

Five studies used fecal samples which were positive for SARS-CoV-2 based on RT-PCR result11-15 and reported achieving viral isolation, and one laboratory study16 found that SARS-CoV-2 infected human small intestinal organoids. A further study visually identified virions in colon tissue.17

Studies using respiratory samples

Six studies on respiratory samples report achieving viral isolation. One study assessed 90 nasopharyngeal samples and cultured 26 of the samples, and positive cultures were only observed up to day eight post symptom onset;4 another study obtained 31 cultures from 46 nasopharyngeal and oropharyngeal samples;18 while 183 nasopharyngeal and sputum samples produced 124 cases in which a cytopathic effect was observed although the denominator of samples taken was unclear.19 Another study in health care workers in UK hospitals isolated one SARS Cov-2 from nineteen specimens in a situation of low viral circulation.20 Two more studies21,22 reported a clear correlation between symptoms onset, date of sampling, Ct and culturability.

Studies using environmental samples

Two possible positive cultures were obtained from 95 environmental samples in one study that assessed the aerosol and surface transmission potential of SARS-CoV-2.23

Mixed sources

Five studies reported viral culture from mixed sources. Using 60 samples from 50 cases of Covid-19, viral culture was achieved from 12 oropharyngeal, nine nasopharyngeal and two sputum samples.5 Jeong et al11 who reported isolation live virus from a stool sample also reported that from of an unreported number of nasopharyngeal, oropharyngeal, saliva, sputum and stool samples, one viral culture was achieved: ferrets
Viral cultures for COVID-19 infectivity assessment – a systematic review

In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Inoculated with these samples became infected; SARS-CoV-2 was isolated from the nasal washes of the two urine-treated ferrets and one stool-treated ferret. An unreported number of samples from saliva, nasal swabs, urine, blood and stool collected from nine Covid-19 patients produced positive cultures and a possible specimen stool culture. One study showed that from nine nasopharyngeal, oropharyngeal, stool, serum and urine samples, all nine were culturable, including two from non-hospitalised Covid-19 patients. Yao and colleagues cultured viable viral isolates from seven sputum samples, three stool samples and one nasopharyngeal sample of 11 patient aged 4 months to 71 years, indicating that the SARS-CoV-2 is capable of replicating in stool samples as well as sputum and the nasopharynx. All samples had been taken within 5 days of symptom onset. The authors also report a relationship between viral load (copy thresholds) and cytopathic effect observed in infected culture cells.

The relationship between RT-PCR results and viral culture of SARS-CoV-2

Eleven studies attempted to quantify the relationship between Cycle threshold and likelihood of culturing live virus. Due to the reporting within the studies it is not possible to currently make a quantitative assessment of the association between RT-PCR results and the success rate of viral culture from the included studies. These studies may be subject to reporting bias. We are, therefore, seeking further information from authors to permit further analysis of the relationship between RT-PCR results and viral culture of SARS-CoV-2.

Duration of viral shedding

Eight studies report on the duration of viral shedding as assessed by PCR for SARS-CoV-2 RNA. The minimum duration of RNA shedding detected by PCR was seven days reported in Bullard, the maximum duration of shedding was 35 days after symptom onset in Qian. Six out of eight studies reported RNA shedding for longer than 14 days (see Table 3).

Discussion

This review shows that a number of studies have attempted and successfully achieved culture of SARS-CoV-2 in the laboratory, using a range of respiratory, fecal or environmentally collected samples. The rate of success is difficult to assess from available studies, and additional studies that we are unaware of may have been performed with no viral culture achieved. There is likely to be a positive relationship between lower cycle count threshold, viral culturability and date of symptom onset. However, more studies with standardised methods are needed to establish the magnitude and reliability of this association.

The purpose of viral testing is to assess the relation of the micro-organism and hazard to humans, i.e. its clinical impact on the individual providing the sample for primary care and the risk of transmission to others for public health. PCR on its own is unable to provide such answers. When interpreting the results of RT-PCR it is important to take into consideration the clinical picture, the cycle threshold value and the number of days from symptom onset to test (STT). Several of our included studies assessed the relationship of these variables and there appears to be a time window during which shedding is at its highest with low cycle threshold and higher possibility of culturing a live virus. We propose that further work should be done on this
with the aim of constructing a calibrating algorithm for PCR which are likely to detect infectious patients. PCR should be continuously calibrated against a reference culture in Vero cells in which cytopathic effect has been observed. Confirmation of visual identification using methods such as an immunofluorescence assay may also be relevant for some virus types. Henderson and colleagues have called for a multicenter study of all currently manufactured SARS-CoV-2 nucleic acid amplification tests to correlate the cycle threshold values on each platform for patients who have positive and negative viral cultures. Calibration of assays could then be done to estimate virus viability from the cycle threshold with some certainty. Ascertaining of infectiousness is all the more important as there is good evidence of viral RNA persistence across a whole range of different viral RNA disease with little or no infectivity in the post infectious phase on MERS, measles, other coronoviridae, HCV and a variety of animal RNA viruses. We are unsure whether SARS CoV-2 methods of cell culture have been standardised. Systems can vary depending upon the selection of the cell lines; the collection, transport, and handling of and the maintenance of viable and healthy inoculated cells. We therefore recommend that standard methods for culture should be urgently developed. If identification of viral infectivity relies on visual inspection of cytopathogenic effect, then a reference culture of cells must also be developed to test recognition against infected cells. Viral culture may not be appropriate for routine daily results, but specialized laboratories should rely on their own ability to use viruses as controls, perform complete investigations when needed, and store representative clinical strains whenever possible. In the absence of a culture, ferret inoculation of specimen washings and antibody titres could also be used. It may be impossible to produce a universal Cycle threshold value as this may change with circumstances (e.g. hospital, community, cluster and symptom level), laboratory methods and the current evidence base is thin.

We suggest the WHO produce a protocol to standardise the use and interpretation of PCR and routine use of culture or animal model to continuously calibrate PCR testing, coordinated by designated Biosafety Level III laboratory facilities with inward directional airflow. The results of our review are similar to those of the living review by Cevick and colleagues. Although the inclusion criteria are narrower than ours, the authors reviewed 79 studies on the dynamics, load and shedding for SARS CoV-1, MERS and SARS CoV-2 from symptoms onset. They conclude that although SARS-CoV-2 RNA shedding in respiratory (up to 83 days) and stool (35 days) can be prolonged, duration of viable virus is relatively short-lived (up to a maximum of 8 days from symptoms onset). Results that are consistent with Bullard et al who found no growth in samples with a cycle threshold greater than 24 or when symptom onset was greater than 8 days. Thus, blanket detection of viral RNA cannot be used to infer infectiousness. Length of excretion is also linked to age, male gender and use of steroids and possible severity of illness. Of note, live virus excretion peaked later in SARS CoV-1 and MERS. The limits of our review are the low number of studies of relatively poor quality with lack of standardised reporting and lack of gold testing for each country involved in the pandemic. This limits our ability to quantify
Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

The current data are suggestive of a relation between the time from collection of a specimen to test, copy threshold, and symptom severity, but the quality of the studies limits firm conclusions to be drawn. We recommend that a uniform international standard for reporting of comparative SARS-CoV-2 culture with index test studies be produced. Particular attention should be paid to the relationship between the results of testing, clinical conditions and the characteristics of the source patients, description of flow of specimens and testing methods. Defining cut off levels predictive of infectivity should be feasible and necessary for diagnosing viral respiratory infections using molecular tests.

We will contact the corresponding authors of the 11 studies correlating ct with likelihood of culture to assess whether it is possible to aggregate data and determine a firm correlation to aid decision making.

Acknowledgments
Drs Susan Amirian, Siyuan Ding, Long Rong and Sravanthi Parasato provided additional information for this brief. Dr Maryanne DeMasi helped with reference identification.

Funding
The review was partly funded by NIHR Evidence Synthesis Working Group project 380 and supported by the Maria and David Willets foundation.

Disclaimer: The article has not been peer-reviewed. The views expressed in this commentary represent the views of the authors and not necessarily those of the host institution, the NHS, the NIHR, or the Department of Health and Social Care. The views are not a substitute for professional medical advice. It will be regularly updated see the evidence explorer at https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/ for regular updates to the evidence summaries and briefs.

Data Availability
All data included in the review are from publications or preprints. All extractions sheets with direct links to the source paper are available from https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/

Authors:
Tom Jefferson is a Senior Associate Tutor and Honorary Research Fellow, Centre for Evidence-Based Medicine, University of Oxford. Disclosure statement is here
Viral cultures for COVID-19 infectivity assessment – a systematic review

In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Elizabeth Spencer is Epidemiology and Evidence Synthesis Researcher at the Centre for Evidence-Based Medicine. (Bio and disclosure statement here)

Jon Brassey is the Director of Trip Database Ltd, Lead for Knowledge Mobilisation at Public Health Wales (NHS) and an Associate Editor at the BMJ Evidence-Based Medicine.

Carl Heneghan is Professor of Evidence-Based Medicine, Director of the Centre for Evidence-Based Medicine and Director of Studies for the Evidence-Based Health Care Programme. (Full bio and disclosure statement here)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References


Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

29. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. Clinical Infectious Diseases 2020; doi: 10.1093/cid/ciaa619
35. Laboratory support for COVID-19 in the EU/EEA. Testing for SARS-CoV-2 virus European Centre for Disease Prevention and Control. 2020
Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review


Figure 1 - PRISMA 2009 Flow Diagram

Records identified through database searching (n = 117)

Additional records identified through other sources (n = 1, unpublished not included)

Records after duplicates removed (n = 118)

Records screened (n = 118)

Records excluded (n = 101)

Full-text articles assessed for eligibility (n = 17)

Full-text articles excluded, with reasons (n = 0)

Studies included in qualitative synthesis (n = 17)

Studies included in quantitative synthesis (meta-analysis) (n = 0)
<table>
<thead>
<tr>
<th>Study</th>
<th>Samples (source)</th>
<th>Samples (n) [SST]</th>
<th>Culture methods</th>
<th>Culture Positive</th>
<th>Additional notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullard</td>
<td>Nasopharyngeal (NP) or endotraacheal (ETT) from COVID-19 patients (mean age 45 years)</td>
<td>90 [0 to 7 days]</td>
<td>NP swabs and ETT specimens in viral transport media were stored at 4°C for 24-72 hours until they were tested for the presence of SARS-CoV-2 RNA using real-time RT-PCR targeting a 122nt portion of the Sarbecovirus envelope gene (E gene). Dilutions were placed onto the Vero cells in triplicate and incubated at 37°C with 5% CO2 for 96 hours. Following incubation of 4 days, cytopathic effect was evaluated under a microscope and recorded.</td>
<td>26</td>
<td>The range of symptoms onset to negative PCT was 21 days. Within this period, positive cultures were only observed up to day 8 post symptom onset</td>
</tr>
<tr>
<td>Huang</td>
<td>Oropharyngeal (OP) or nasopharyngeal (NP) swabs, or sputum (SP)</td>
<td>60 specimens</td>
<td>SARS-CoV-2 cDNA was prepared using RNA extracted from the specimens of the first patient with confirmed COVID-19. RT was performed using the MMLV Reverse transcription kit. All procedures for viral culture were conducted in a biosafety level-3 facility. Vero-E6 and MK-2 (ATCC) cells were maintained in a virus culture medium and the cells were maintained in a 37°C incubator with daily observations of the cytopathic effect.</td>
<td>12 OP, 9 NP and two from SP specimens were culturable</td>
<td>Specimens with high copy numbers of the viral genome, indicative of higher viral load, were more likely to be culturable.</td>
</tr>
<tr>
<td>Jeong</td>
<td>Naso/oropharyngeal swabs, saliva, urine, and stool</td>
<td>5 patients</td>
<td>Specimens positive by qPCR were subjected to virus isolation in Vero cells. Urine and stool samples were inoculated intranasally in ferrets and they evaluated the virus titer in nasal washes on 2, 4, 6, and 8 days post-infection (dpi). Immunofluorescence antibody assays were also done.</td>
<td>Naso/oropharyngeal saliva, urine and stool Samples were collected between days 8 to 30 of the clinical course. Viable SARS-CoV-2 was isolated from 1 naso/oropharyngeal swab. Ferrets inoculated with patient urine or stool were infected. SARS-CoV-2 was isolated from the nasal washes of the 2 urine-</td>
<td>Viral loads in urine, saliva, and stool samples were almost equal to or higher than those in naso/oropharyngeal swabs. After symptom resolution, patients shed viable virus in their saliva and urine up to day 15 of illness.</td>
</tr>
<tr>
<td>Reference</td>
<td>Description</td>
<td>Methods</td>
<td>Results</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qian</td>
<td>Rectal tissue obtained from a surgical procedure was available.</td>
<td>Ultrathin sections of tissue fixed in epoxy resin on formvar-coated copper grids were observed under electron microscope under 200kV. Immunohistochemical staining was used to establish expression and distribution of SARS-CoV-2 antigen.</td>
<td>1 treated ferret and one stool-treated ferret. No culture performed. Visualisation of virions in rectal tissue and detection of SARS-CoV-2 antigen in the rectal tissue.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang</td>
<td>Bronchoalveolar fluid, sputum, feces, blood, and urine specimens from hospital in-patients with COVID-19</td>
<td>4 fecal samples with sufficiently high copy numbers from 1,070 specimens collected from 205 patients with COVID-19 (mean age of 44 years and 68% male [1 to 3 days from hospital admission]) rRT-PCR targeting the open reading frame 1ab gene of SARS-CoV-2; cycle threshold values of rRT-PCR were used as indicators of the copy number of SARS-CoV-2 RNA in specimens with lower cycle threshold values corresponding to higher viral copy numbers. A cycle threshold value less than 40 was interpreted as positive for SARS-CoV-2 RNA. Four SARS-CoV-2 positive fecal specimens with high copy numbers were cultured, and then electron microscopy was performed to detect live virus.</td>
<td>4 viewed by electron microscope. The details of how the 4 samples were cultured were not reported. The patients did not have diarrhoea.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xiao F. Sun</td>
<td>Serial feces samples collected from 28 hospitalised COVID-19 patients: 3 samples from 3 RNA-positive patients were tested for possible viral culture.</td>
<td>3, one patient admitted day 7 post onset Inoculation of Vero 6 cells. Cycle threshold values for the fecal sample were 23.34 for the open reading frame 1ab gene and 20.82 for the nucleoprotein gene. A cytopathic effect was visible in Vero E cells 2 days after a second-round passage. The researchers negatively stained culture supernatant and visualized by transmission electron microscopy. Viral particles that were visible were spherical and had distinct surface spike protein projections, consistent with a previously published SARS-CoV2 image.</td>
<td>2/3 (infectious virus was present in faeces from two cases) Selection of samples is not entirely clear.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arons</td>
<td>nasopharyngeal and oropharyngeal swabs</td>
<td>46 rRT-PCR–positive specimens [For asymptomatic patients all rRT-PCR positive samples shipped to USA CDC for viral culture using Vero-CCL-81 cells. Cells showing cytopathic effects were used for SARS-CoV-2 rRT-PCR to isolate from 6 days before to 9 days after symptom.</td>
<td>31 [no relation to symptoms presence. Culturable virus is isolated from 6 days before to 9 days after symptom.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Viral cultures for COVID-19 infectivity assessment – a systematic review

**In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review**

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample Type</th>
<th>Sample Description</th>
<th>Methodology</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>La Scola</td>
<td>Nasopharyngeal swabs or sputum samples</td>
<td>183 (4384 samples from 3466 patients) (not reported)</td>
<td>Confirm isolation and viral growth in culture.</td>
<td>Of the 183 samples inoculated in the studied period of time, 129 led to virus isolation. Of these 124 samples had detectable cytopathic effect between 24 and 96 h</td>
</tr>
<tr>
<td>Santarpia</td>
<td>Windowsill and air, mean 7.3 samples per room. The percentage of PCR positive samples from each room was 40% - 100%</td>
<td>13 patients [days 5 to 9 and day 18 of isolation in a quarantine unit]</td>
<td>Vero E6 cells were used to culture virus from environmental samples. The cells were cultured in Dulbecco’s minimal essential medium (DMEM) supplemented with heat inactivated fetal bovine serum (10%), Penicillin/Streptomycin (10,000 IU/mL &amp;10,000 μg/mL) and Amphotericin B (25 μg/mL).</td>
<td>Possibly 2 with weak cytopathic effect</td>
</tr>
<tr>
<td>Wölfer</td>
<td>Saliva, nasal swabs, urine, blood and stool</td>
<td>9 patients [2 to 4 days]</td>
<td>The average virus RNA load was 6.76 × 105 copies per the whole swab until day 5, and the maximum load was 7.11 × 108 copies per swab. The last swab sample that tested positive was taken on day 50 after the onset of symptoms.</td>
<td>Yes in respiratory samples, and indicative in stool</td>
</tr>
<tr>
<td>Kujawski</td>
<td>Nasopharyngeal (NP), oropharyngeal (OP), stool, serum and urine</td>
<td>9 from 9 patients</td>
<td>SARS-CoV-2 real-time PCR with reverse transcription (rRT–PCR) cycle threshold (Ct) values of virus isolated from the first tissue</td>
<td>Viable SARS-CoV-2 was cultured at day 9 of illness (patient 10), but was not</td>
</tr>
</tbody>
</table>

---

La Scola 19
Santarpia 23
Wölfer 24
Kujawski 25

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
<table>
<thead>
<tr>
<th>Investigation Team)</th>
<th>specimens</th>
<th>culture passage were 12.3 to 35.7 and for one patient, virus isolated from tissue culture passage 3 had a titer of $7.75 \times 10^7$ median tissue culture infectious dose per ml; these data were likely more reflective of growth in tissue culture than patient viral load.</th>
<th>attempted on later specimens. SARS-CoV-2 rRT–PCR Ct values of virus isolated from the first tissue culture passage were 12.3 to 35.7. Mean Ct values in positive specimens were 17.0 to 39.0 for NP, 22.3 to 39.7 for OP and 24.1 to 39.4 for stool. All blood and urine isolates were negative. Ct values of upper respiratory tract specimens were lower in the first week of illness than the second in most patients, low Ct values continued into the second and third week of illness.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhang</td>
<td>Stool</td>
<td>Unknown [not reported]</td>
<td>We do not know what influenced successful virus culture e.g. methods optimal, or concentration of virus optimal. More information needed.</td>
</tr>
<tr>
<td>Xiao F. Tang, M15</td>
<td>Esophageal, gastric, duodenal, and rectal tissues were obtained from 1 COVID-19 patients by endoscopy.</td>
<td>1 plus an unknown additional number of fecal samples from RNA-positive patients. [not reported]</td>
<td>1/1 RNA-positive patient. Positive staining of viral nucleocapsid protein was visualized in the cytoplasm of gastric, duodenal, and rectum glandular epithelial cell, but not in esophageal epithelium of the 1 patient Total sample numbers are not reported.</td>
</tr>
</tbody>
</table>
### Viral cultures for COVID-19 infectivity assessment – a systematic review

**In:** Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample</th>
<th>Patients</th>
<th>Sample Collection</th>
<th>Sample Processing</th>
<th>Virus Assay</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yao</td>
<td>Sputum (n=7), stool (n=3) and one nasopharyngeal sample</td>
<td>11 patients admitted to hospital: 9 classified as serious or critical, 1 moderate, 1 mild symptoms [0 to 16 days]</td>
<td>The samples of the 11 patients involved in this study were collected during the early phase of the Covid-19 break out in China, dates ranging from 2nd of January to the 2nd of April 2020. All except one of the patients had moderate or worse symptoms. Three patients had co-morbidities and one patient needed ICU treatment. Seven patients had sputum samples, one nasopharyngeal and three had stool samples</td>
<td>The samples were pre-processed by mixing with appropriate volume of MEM medium with 2% FBS, Amphotericin B, Penicillin G, Streptomycin and TPCK-trypsin. The supernatant was collected after centrifugation at 3000 rpm at room 434 temperature. Before infecting Vero-E6 cells, all collected supernatant was filtered using a 435 0.45 µm filter to remove cell debris etc.</td>
<td>Vero-E6 cells were infected with 11 viral isolates and quantitatively assessed their viral load at 1, 2, 4, 8, 24, and 48 hours post-infection (PI) and their viral cytopathic effects (CPE) at 48 and 72 hours PI and examined whether the viral isolates could successfully bind to Vero-E6 243 cells as expected.</td>
<td>Cultured viruses were inoculated in Vero cells. At 8 hours post-infection there was a significant decrease in Ct value (increases in viral load) for five isolates. At 24 hours significant decreases in the Ct values for all of the viral isolates were observed. Mutations of the viruses are also reported</td>
</tr>
</tbody>
</table>

Cultured viruses were inoculated in Vero cells. At 8 hours post-infection there was a significant decrease in Ct value (increases in viral load) for five isolates. At 24 hours significant decreases in the Ct values for all of the viral isolates were observed. Mutations of the viruses are also reported.
### Viral cultures for COVID-19 infectivity assessment – a systematic review

In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

<table>
<thead>
<tr>
<th>Study</th>
<th>Samples Description</th>
<th>Positive Cases</th>
<th>Vero E6 Cells Inoculation</th>
<th>Cultivable Virus Correlation</th>
<th>Culturable Virus Cultivation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Singanayagam</td>
<td>324 samples: nose, throat, combined nose-and throat and nasopharyngeal swabs and aspirates</td>
<td>253 positive case [-10 to 60 days]</td>
<td>Vero E6 cells were inoculated with clinical specimens and incubated at 37 °C, 5% CO₂. Cells were inspected for cytopathic effect daily up to 14 days. Presence of SARS-CoV-2 was confirmed by SARS-CoV-2 nucleoprotein staining by enzyme immunoassay on infected cells.</td>
<td>RT-PCR cycle threshold values correlate strongly with culturable virus i.e. likelihood of infectiousness. Median Ct of all 324 samples was 31.15. Probability of culturing virus declines to 8% in samples with Ct &gt; 35 and to 6% 10 days after onset and was similar in asymptomatic and symptomatic persons. Asymptomatic persons represent a source of transmissible virus but there is no difference in Ct values and culturability by age group.</td>
<td>133 (41%) samples (from 111 cases)</td>
</tr>
<tr>
<td>Perera</td>
<td>68 specimens: nasopharyngeal aspirates combined with throat swab (n=49), nasopharyngeal aspirate (n=2), nasopharyngeal swab combined with throat swab (n=3), nasopharyngeal swab (n=2), sputum (n=11) and saliva (n=1).</td>
<td>35 patients, 32 with mild disease [1 to 67 days]</td>
<td>Specimens were tested for sgRNA with ≥5 log10 N gene copies per mL. The complementary DNA obtained was subjected to PCR (40 cycles). Vero E6 cells were seeded and incubated for 24 hours in a CO₂ incubator. The culture medium was removed and 125 μL of the clinical specimen in virus transport medium diluted and was inoculated into 2 wells. After 2 hours incubation in a CO₂ incubator at 37°C, the plates were incubated at 37°C in a CO₂ incubator. A sample (100 μL) of supernatant was sampled for a quantitative real-time RT-PCR at 0 and 72 hours post inoculation. At 72 hours, cells were scraped into the supernatant and transferred onto fresh cells in 24-well plates and monitored for an additional 72 hours. A final quota of cells was collected for quantitative real-time RT-PCR. Cells were observed for cytopathic effect daily and harvested for testing if 25%–50% of cells</td>
<td>16/35 at a median 26 Ct</td>
<td>Culturable SARS CoV-2 and sub-genomic RNA (good indicator of replication) was rarely detectable beyond 8 days after onset of illness although virus RNA by RT-PCR remained for up to 70 days.</td>
</tr>
</tbody>
</table>

www.cebm.net/evidence-synthesis
Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Specimens</th>
<th>Detection Method</th>
<th>Viral Isolation</th>
<th>Clinical Relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown</td>
<td>Combined viral throat and nose swab from each participant n=1,152</td>
<td>Health care workers in six UK hospitals</td>
<td>Specimens were sent on the same day for detection of SARS-CoV-2 RNA by RT-PCR to the PHE national reference laboratory (five hospitals) or one hospital laboratory. The PHE laboratory used an Applied Biosystems 7500 FAST system targeting a conserved region of the SARS-CoV-2 open reading frame (ORF1ab) gene. The hospital laboratory used a different CE-IVD kit, targeting 3 SARS-CoV-2 genes (RdRp, E, and N). Both PCRs had internal controls. Viral culture of PHE laboratory positives was attempted in Vero E6 cells with virus detection confirmed by cytopathic effect up to 14 days post-inoculation.</td>
<td>SARS-CoV-2 virus was isolated from only one (5%) of nineteen cultured samples. It had a Ct value of 26.2.</td>
<td>Symptoms in the past month were associated with threefold increased odds of testing positive (aOR 3.46, 95% CI 1.38 to 8.67; p = 0.008). 23 of 1,152 participants tested positive (2.0%) with a median Ct of 35.70 (IQR:32.42 to 37.57).</td>
</tr>
</tbody>
</table>

Table 1. Characteristics of included studies. Key: STT = symptom onset to test date.
<table>
<thead>
<tr>
<th>Study</th>
<th>Description of methods and sufficient detail to replicate</th>
<th>Sample sources clear</th>
<th>Analysis &amp; reporting appropriate</th>
<th>Is bias dealt with</th>
<th>Applicability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullard 2020**</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Santarpia 2020*</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Wölfel 2020*</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Huang 2020**</td>
<td>yes</td>
<td>Yes</td>
<td>yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Wang W 172020</td>
<td>No</td>
<td>Yes</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
</tr>
<tr>
<td>Zhang Y 2020*</td>
<td>Partly</td>
<td>Yes</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
</tr>
<tr>
<td>Xiao 2020b**</td>
<td>No</td>
<td>Yes</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
</tr>
<tr>
<td>Qian Q 2020**</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Arons 2020*</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>yes</td>
<td>unclear</td>
</tr>
<tr>
<td>Xiao F 2020b</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
</tr>
<tr>
<td>Kujawski 2020**</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Jeong 2020*</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
</tr>
<tr>
<td>La Scola 2020*</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Yoa H 2020*</td>
<td>Yes</td>
<td>Yes</td>
<td>yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Singanayagam**</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Perera 21*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Brown**</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>unclear</td>
<td>unclear</td>
</tr>
</tbody>
</table>

Table 2. Quality of included studies
### Table 3. Duration of viral shedding in the included studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>Duration of viral shedding as assessed by PCR for SARS-CoV-2 RNA</th>
<th>Range of duration</th>
<th>Median of duration</th>
<th>Notes on clinical course</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullard$^4$</td>
<td>Day 0 to day 7 at least.</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Jeong$^{11}$</td>
<td>At least 8 days to at least 30 days</td>
<td>NR</td>
<td>NR</td>
<td>5 positive-PCR patients, day 8 to day 30 after symptom onset. At the time of sampling, patients 1, 2, 3, and 5 were on days 8, 13, 11, and 30 of illness, respectively, and their clinical symptoms had resolved completely. Patient 4 was on day 15 of illness with a ventilator and extracorporeal membrane oxygenation support. All clinical specimens collected from the five patients were positive for the SARS-CoV-2 spike gene by qPCR, even though four of the patients no longer displayed clinical symptoms.</td>
</tr>
<tr>
<td>Qian$^{17}$</td>
<td>SARS-CoV-2 RNA detected day 10 to between day 18 and day 35 after symptom onset.</td>
<td>Covid-19 symptoms began on day 3 after surgery on day 0. SARS-CoV-2 PCR test done on day 7 after surgery. PCR on day 14 and day 18 post-surgery were positive. PCR on day 37 and day 38 after surgery were negative. Patient was discharged on day 41 after surgery following the 2 sequential negative PCR tests plus absence of clinical symptoms.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

<table>
<thead>
<tr>
<th>Study</th>
<th>Duration of SARS-CoV-2 detection</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xiao F, Sun J</td>
<td>Day 7 after symptom onset to at least day 28.</td>
<td>1 patient. SARS-CoV-2 RNA PCR positive at day 7 after symptom onset. Patient died two weeks after final sample.</td>
</tr>
<tr>
<td>Wölfel</td>
<td>Up to day 28 after onset of symptoms.</td>
<td>9 cases. All swabs taken between day 1 and day 5 were positive by PCR. Virus could not be isolated from samples taken after day 8 even among cases with ongoing high viral loads of approximately 105 RNA copies/mL</td>
</tr>
<tr>
<td>Kujawski</td>
<td>Duration of SARS-CoV-2 detection by RT-PCR was 7 to 22 days</td>
<td>First 12 identified patients in the US. Respiratory specimens collected between illness days 1 to 9 (median, day 4) All patients had SARS-CoV-2 RNA detected in respiratory specimens, typically for 2 to 3 weeks after illness onset. Mean duration of fever was 9 days. Two patients received a short course of corticosteroids.</td>
</tr>
<tr>
<td>Xiao, Tang M</td>
<td>1 to 12 days (stool samples) Duration of detection of SARS-CoV-2 respiratory samples not reported.</td>
<td>Positive stool results duration ranged from 1 to 12 days. 17 (23%) patients continued to have positive results in stool after showing negative results in respiratory samples.</td>
</tr>
</tbody>
</table>

Fecal samples day 35 after discharge were negative.
| Singanayagam \(^2\) | At least day 20 post symptom onset, upper respiratory tract swabs PCR | NR | NR | Median duration of virus shedding as measured by viral culture was 4 days (IQR: 1 to 8; range: −13 to 12, with symptom onset dates based on symptom recall) |